3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors ; day:28 ; month:10 ; year:2024 ; pages:1-8
Journal of thrombosis and thrombolysis ; (28.10.2024), 1-8
- Creator
-
Hays, William Blake
Billups, Kelsey
Nicholson, Jessica
Bailey, Abby M.
Gregory, Haili
Weeda, Erin R.
Weant, Kyle A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11239-024-03052-4
- URN
-
urn:nbn:de:101:1-2501172123469.948127505046
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hays, William Blake
- Billups, Kelsey
- Nicholson, Jessica
- Bailey, Abby M.
- Gregory, Haili
- Weeda, Erin R.
- Weant, Kyle A.
- SpringerLink (Online service)
Other Objects (12)
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Role of prothrombin complex concentrate in perioperative coagulation therapy
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Role of prothrombin complex concentrate in perioperative coagulation therapy
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Role of prothrombin complex concentrate in perioperative coagulation therapy
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis